Metastatic colorectal cancer

Current Treatment Options in Oncology

Volumn 2, Issue 6, 2001, Pages 459-471

  Kindler, Hedy Lee ^a   Shulman, Keith L ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Capecitabine; Clin Oncol; Colorectal Cancer; Irinotecan; Oxaliplatin

Indexed keywords

ANTINEOPLASTIC AGENT;

ADENOCARCINOMA; COLORECTAL TUMOR; EPIDEMIOLOGY; HEPATIC ARTERY; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; LIVER TUMOR; LUNG TUMOR; METASTASIS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; REVIEW;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; EPIDEMIOLOGIC METHODS; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; LUNG NEOPLASMS;

EID: 0035749403     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-001-0068-7     Document Type: Article

References (47)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M: Cancer statistics 2001. CA Cancer J Clin 2001, 51:15–36. DOI: 10.3322/canjclin.51.1.15
2. Kroser JA, Bachwich DR, Lichtenstein GR: Risk factors for the development of colorectal carcinoma and their modification. Hematol Oncol Clin North Am 1997, 11:547–577. DOI: 10.1016/S0889-8588(05)70451-2
3. Kindler HL, Schilsky RL: Colorectal cancer. In In Oncologic Therapies, edn. 2. Edited by: Vokes EE, Golomb HM. Berlin, Springer-Verlag, in press.
4. Simmonds PC: Palliative chemotherapy for advanced colorectal cancer: systematic review and metaanalysis. Colorectal Cancer Collaborative Group. BMJ 2000, 321:531–535. DOI: 10.1136/bmj.321.7260.531
5. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992, 10:896–903.
6. Meta-analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998, 16:301–308.
7. Leichman C, Fleming T, Muggia F, et al.: Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 1995, 13:1303–1311.
8. Shimada Y, Yoshino M, Wakui A, et al.: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 1993, 11:909–913.
9. Rougier P, Bugat R, Douillard J, et al.: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997, 15:251–260.
10. Pitot HC, Wender DB, O’Connell MJ, et al.: Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997, 15:2910–2919.
11. Conti JA, Kemeny NE, Saltz LB, et al.: Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996, 14:709–715.
12. Cunningham D, Pyrhonen S, James R, et al.: Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998, 352:1413. DOI: 10.1016/S0140-6736(98)02309-5
13. Rougier P, VanCutsem E, Bajetta E, et al.: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998, 352:1407–1412. DOI: 10.1016/S0140-6736(98)03085-2
14. Saltz LB, Cox JV, Blanke C, et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. New Engl J Med 2000, 343:905–914. The randomized phase III trial that established the superiority of the three-drug regimen of 5-FU, leucovorin, and irinotecan in terms of response rate, survival, and progression-free survival. DOI: 10.1056/NEJM200009283431302
15. Douillard J, Cunningham D, Roth A, et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 2000, 355:1041–1047. DOI: 10.1016/S0140-6736(00)02034-1
16. Sargent DJ, Niedzwiecki D, O’Connell MJ, Schilsky RL: Recommendations for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. New Engl J Med 2001, 344:1. An important letter to the editor that alerts clinicians to the potential toxicities of combination therapy with 5-FU, leucovorin, and irinotecan.
17. vanCutsem E, Findlay M, Osterwalder B, et al.: Capecitabine, an oral fluoropyrimidine with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 2000, 18:1337–1345.
18. Hoff P, Ansari R, Batist G, et al.: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001, 19:2282–2292.
19. Sharma S, Saltz LB: Oral chemotherapeutic agents for colorectal cancer. Oncologist 2000, 5:99–107. Reviews the economic considerations for the development of oral regimens for colorectal cancer. DOI: 10.1634/theoncologist.5-2-99
20. Cromheecke M, de Jong KP, Hoekstra HJ: Current treatment for colorectal cancer metastatic to the liver. Eur J Surg Oncol 1999, 25:451–463. An excellent review of treatment strategies for colorectal cancer metastatic to the liver. DOI: 10.1053/ejso.1999.0679
21. Fong Y, Cohen AM, Fortner JG, et al.: Liver resection for colorectal metastases. J Clin Oncol 1997, 15:938–946.
22. Bilchik AJ, Wood TF, Allegra D, et al.: Cryosurgical ablation and radiofrequency ablation for unresectable hepatic neoplasms: a proposed algorithm. Arch Surg 2000, 135:657–664. DOI: 10.1001/archsurg.135.6.657
23. Girard P, Ducreeux M, Baldeyrou P, et al.: Surgery for lung metastases from colorectal cancer: analysis of prognostic factors. J Clin Oncol 1996, 14:2047–2053.
24. Tebbutt NC, Norman A, Livingston S, et al.: Chemotherapy as initial treatment in patients with unresected primary colorectal cancer and synchronous metastases. Proc Am Soc Clin Oncol 2001, 20:524.
25. Meta-analysis Group in Cancer: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996, 88:252–258. DOI: 10.1093/jnci/88.5.252
26. Haller DG: Waiting for the definitive trial of hepatic arterial chemotherapy for colorectal cancer. J Clin Oncol 2000, 18:239–242. A thoughtful discussion of the problems and promise of trials using hepatic arterial infusion.
27. Lorenz M, Muller HH, for the German Cooperative Group on Liver Metastases: Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 2000, 18:243–254.
28. Kemeny N, Huang Y, Cohen A, et al.: Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999, 341:2039. DOI: 10.1056/NEJM199912303412702
29. Becouarn Y, Yehou M, Ducreux M, et al.: Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer. J Clin Oncol 1998, 16:2739–2744.
30. Machover D, Diaz-Rubio E, deGramont A, et al.: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996, 7:95–98.
31. de Gramont A, Figer A, Seymour M, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18:2938–2947. An important trial that demonstrates that the addition of oxaliplatin to 5-FU and leucovorin significantly improves response rates, but not survival.
32. Zalcberg JR, Cunningham D, vanCutsem Cutsem E, et al.: ZD1694: a novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex colorectal study group. J Clin Oncol 1996, 14:716–721.
33. Pazdur R, Vincent M: Raltitrexed (Tomudex) versus 5-fluorouracil and leucovorin (5-FU + LV) in patients with advanced colorectal cancer (ACC): results of a randomized, multicenter, North American trial. Proc Am Soc Clin Oncol 1997, 16:801.
34. Blanke CD, Kasimis B, Schein P, et al.: Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer. J Clin Oncol 1997, 15:915–920.
35. Punt CJ, Keizer HJ, Douma J, et al.: Multicenter randomized trial of 5-Flourouracil (5-FU) and leucovorin (LV) with or without trimetrexate (TMTX) as first-line treatment in patients (pts) with advanced colorectal cancer (ACC). Proc Am Soc Clin Oncol 1999, 18:1006.
36. John W, Picus J, Blanke CD, et al.: Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study. Cancer 2000, 88:1807–1813. DOI: 10.1002/(SICI)1097-0142(20000415)88:8<1807::AID-CNCR8>3.0.CO;2-L
37. Bollag DM, McQueney PA, Zhu J, et al.: Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995, 55:2325–2333.
38. Pazdur R, Lassere Y, Rhodes V, et al.: Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994, 12:2296–2300.
39. Kindler HL, Schilsky RL: Eniluracil. Expert Opin Investig Drugs 2000, 9:1635–1649. DOI: 10.1517/13543784.9.7.1635
40. Ohtsu A, Baba H, Sakata Y, et al.: Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer 2000, 83:141–145. DOI: 10.1054/bjoc.2000.1236
41. Saltz L, Rubin M, Hochster H, et al.: Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001, 20:3a. This important trial demonstrates the activity of the combination of a monoclonal antibody to the epidermal growth factor receptor plus irinotecan in patients refractory to irinotecan.
42. Ciardiello F, Caputo R, Bianco R, et al.: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000, 6:2053–2063.
43. Bergsland E, Hurwitz H, Fehrenbacher L, et al.: A randomized phase II trial comparing rhuMAb VEGF (Recombinant Humanized monoclonal antibody to vascular endothelial growth factor) plus 5-FU/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2000, 19:242a.
44. Eng C, Kindler HL, Stadler WM, et al.: SU5416 in advanced colorectal cancer (CRC): a University of Chicago phase II consortium study. Proc Am Soc Clin Oncol 2001, 20:116b.
45. Hwang J, Sinicrope F, Safran H, et al.: A Phase II Trial of Irinotecan and Trastuzumab (Herceptin) in Patients (Pts) Overexpressing HER-2/neu in Metastatic Colorectal Cancer (CRC). Proc Am Soc Clin Oncol 2001, 20:142a.
46. Foon KA, John WJ, Chakraborty M, et al.: Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol 1999, 17:2889–2895.
47. Twelves C, Harper P, Cutsem EV, et al.: A phase III trial (SO14796) of Xeloda (Capecitabine) in previously untreated advanced/metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999, 18:1010a.